Additionally, KRAS pathway accelerates RAF/ERK and PI3K/AKT signaling, which results in increased cell proliferation and suppressed apoptosis in sorafenib-resistant HCC cells [6]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.